EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Effect of Left Atrial Size and Volume Reduction on Pulmonary Vein Isolation Efficacy in Patients With Persistent and Longstanding Persistent Atrial Fibrillation: Subset Analysis From the aMAZE Trial

Dhanunjaya Lakkireddy iD, David J Wilber iD, Suneet Mittal iD, David Rene Tschopp iD, Christopher R Ellis iD, Abdi Rasekh iD, Troy Hounshell iD, Robert Hoyt iD, Rudolph F Evonich, Sheetal Chandhok iD, Ronald D Berger iD, Rodney Horton iD und 17 weitere

Circulation: Arrhythmia and Electrophysiology · 2026-08 · 19 (8)

DOI: 10.1161/circep.125.014755 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Arrhythmia and Electrophysiology, 2026-08. Verfasst von Dhanunjaya Lakkireddy und 28 weiteren Autor:innen. Beteiligte Einrichtung: Kansas City Heart Rhythm Institute, Overland Park (D.L., A.K.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Pulmonary Veins, Catheter Ablation, Heart Atria. Die Arbeit nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Large left atrial volume (LAV) is a strong predictor of advanced left atrial substrate and is associated with less successful outcomes following pulmonary vein isolation (PVI) alone. Prespecified variables of the aMAZE trial (Left Atrial Appendage Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation) were evaluated to access for the impact of LAV and left atrial appendage ligation on atrial fibrillation (AF) outcomes. METHODS: The aMAZE trial was a multicenter, randomized-controlled study evaluating the effects of LAV on freedom from atrial arrhythmias (AA) following PVI-only compared with LARIAT and PVI (LARIAT+PVI). In total, 610 drug-refractory patients with nonparoxysmal AF were randomized 2:1 to LARIAT versus PVI alone. Freedom from AA was assessed 12 months postprocedure. LAV was independently assessed by a core laboratory from cardiac computed tomography performed before ablation. (REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02513797) RESULTS: There were 404 patients in the LARIAT+PVI group and 206 in the PVI-only group. Logistic regression performed within each subgroup for primary effectiveness with LAV demonstrated that the recurrence of AA after PVI was directly related to increasing LAV. Freedom from recurrence of AA in the LARIAT+PVI arm was independent and preserved irrespective of LAV. Similar results were seen with LAV index. A tercile analysis of early persistent AF (perAF) patients (AF >7 days and 148 cm 3 ) LAV tercile showed statistically significant freedom from AA compared with PVI-only (69% versus 49%; P =0.02). Significant differences ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationPulmonary VeinsCatheter AblationHeart AtriaAtrial Function, LeftAtrial AppendageHumansFemaleMaleMiddle AgedTime FactorsLeft Atrial Appendage ClosureTreatment OutcomeLigationAgedAction PotentialsRecurrenceHeart Rate

Stichwörter der Autor:innen

atrial fibrillation burdenleft atrial appendage ligationleft atrial volume

Autor:innen und Institutionen

  • Kansas City Heart Rhythm Institute, Overland Park (D.L., A.K.).
  • Loyola University Chicago Stritch School of Medicine, Maywood, IL (D.J.W., S.V.).
  • Valley Health System, Ridgewood, NJ (S.M.).
  • Texas Cardiac Arrhythmia Institute, Austin (D.R.T., R. Horton, A.N.).
  • Vanderbilt University Heart-EP, Nashville, TN (C.R.E.).
  • Baylor College of Medicine, Houston, TX (A.R.).

ORCID-Profile: Dhanunjaya Lakkireddy, David J Wilber, Suneet Mittal, David Rene Tschopp, Christopher R Ellis, Abdi Rasekh, Troy Hounshell, Robert Hoyt, Sheetal Chandhok, Ronald D Berger, Rodney Horton, Michael Hoskins, Hugh Calkins, Steven J Yakubov, Omar K Khalique, Todd Cory Pulerwitz, Nitish Badhwar, Thomas Dewland, Stanislav Weiner, Smit Valsaiwala, Aashish Katapadi, Patrick Walker, Luigi DiBiase, Andrea Natale, Randall J Lee

Zitieren

APA

Lakkireddy, D., Wilber, D. J., Mittal, S., Tschopp, D. R., Ellis, C. R., Rasekh, A., Hounshell, T., Hoyt, R., Evonich, R. F., Chandhok, S., Berger, R. D., Horton, R., Hoskins, M., Calkins, H., Yakubov, S. J., Khalique, O. K., Pulerwitz, T. C., Badhwar, N., Dewland, T., …, & aMAZE Investigators (2026). Effect of Left Atrial Size and Volume Reduction on Pulmonary Vein Isolation Efficacy in Patients With Persistent and Longstanding Persistent Atrial Fibrillation: Subset Analysis From the aMAZE Trial. Circulation: Arrhythmia and Electrophysiology, 19(8). https://doi.org/10.1161/circep.125.014755

Vancouver

Lakkireddy D, Wilber DJ, Mittal S, Tschopp DR, Ellis CR, Rasekh A, et al. Effect of Left Atrial Size and Volume Reduction on Pulmonary Vein Isolation Efficacy in Patients With Persistent and Longstanding Persistent Atrial Fibrillation: Subset Analysis From the aMAZE Trial. Circulation: Arrhythmia and Electrophysiology. 2026;19(8). doi:10.1161/circep.125.014755

BibTeX
@article{Lakkireddy2026,
  author = {Lakkireddy, Dhanunjaya and Wilber, David J and Mittal, Suneet and Tschopp, David Rene and Ellis, Christopher R and Rasekh, Abdi and Hounshell, Troy and Hoyt, Robert and Evonich, Rudolph F and Chandhok, Sheetal and Berger, Ronald D and Horton, Rodney and Hoskins, Michael and Calkins, Hugh and Yakubov, Steven J and Khalique, Omar K and Pulerwitz, Todd Cory and Badhwar, Nitish and Dewland, Thomas and Weiner, Stanislav and Valsaiwala, Smit and Katapadi, Aashish and Simons, Pamela and Walker, Patrick and Ndilkintum, Nifi and DiBiase, Luigi and Natale, Andrea and Lee, Randall J and aMAZE Investigators, aMAZE Investigators},
  title = {Effect of Left Atrial Size and Volume Reduction on Pulmonary Vein Isolation Efficacy in Patients With Persistent and Longstanding Persistent Atrial Fibrillation: Subset Analysis From the aMAZE Trial},
  journal = {Circulation: Arrhythmia and Electrophysiology},
  year = {2026},
  volume = {19},
  number = {8},
  doi = {10.1161/circep.125.014755}
}
Kostenlos starten →